MYOS RENS is evaluating the genotypic characteristics and molecular pathways that contribute to the changes seen in muscle and inflammatory disease states associated with sarcopenia and related disorders.
MYOS RENS takes its responsibility to the environment and the community very seriously. MYOS RENS is committed to being a good corporate citizen and welcomes suggestions on enhancing our contributions in this regard.
New, High-Quality Nutrition Product Now Eligible for Medicare and Medicaid Reimbursement
Underpins Launch of MYOS Medical Nutrition, Fully Leveraging the Versatility of Fortetropin®
CEDAR KNOLLS, N.J., Oct. 2, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company [...]
CEDAR KNOLLS, N.J., Sept. 26, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today that MYOS will exhibit at [...]